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Abstract 25 
Meta-analysis based on Individual Participant Data (IPD), often described as the ‘gold 26 
standard’ for effectiveness evidence synthesis, is increasingly being deployed despite being 27 
more resource intensive than collating study-level results. Its professed virtues include the 28 
ability to incorporate unreported data and to standardise variables and their definitions across 29 
trials. In reality, the unreported data, even though present in shared datasets might still not be 30 
usable in the analysis. The characteristics of trial participants and their outcomes may be too 31 
diversely captured for harmonisation, and too time-and-resource-consuming to standardise. 32 
Embarking on an IPD meta-analysis can lead to unanticipated challenges which ought to be 33 
handled with pragmatism. The aim of this article is to discuss the opportunities created by 34 
access to IPD and the practical limitations placed on such meta-analyses, using an 35 
international IPD meta-analysis of trials on the effect of lifestyle interventions in pregnancy 36 
as an exemplar. Despite the increasing uptake of IPD meta-analysis, they encounter old 37 
problems shared by other research methods. When embarking on IPD meta-analysis, it is 38 
essential to evaluate the trade-offs between the ambitions, and what is achievable due to 39 
constraints imposed by the condition of collected IPD. Furthermore, incorporation of 40 
aggregate data from trials where IPD was not available should be a mandatory sensitivity 41 
analysis that makes the evidence synthesis up-to-date.  42 
 43 
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Introduction 46 
Meta-analysis using Individual Participant Data (IPD) is becoming increasingly popular 47 
despite being a laborious and resource-intensive method of evidence synthesis compared to a 48 
standard review using study-level data.1 It has the potential to overcome limitations of meta-49 
analyses based on published data through access to raw trial data1-4 such as standardisation of  50 
analysis methods and data across trials1,5 (Table 1). Access to IPD can facilitate integrity 51 
checks and intention to treat analysis by imputing for missing data. Collation of rarely 52 
reported variables for the key outcomes can result in greater precision of the intervention 53 
effect and address the problem of selective reporting.1 54 
 55 
Existing methodological literature focuses mainly on cost, team’s expertise and management 56 
of the collaboration.3 Yet, not much is available on practical challenges associated with data 57 
harmonisation and their consequences for IPD meta-analyses. The aim of this article is to 58 
discuss the some of the opportunities created by access to IPD and the limitations of meta-59 
analysis using IPD as indicated in Table 1. We use  the i-WIP IPD meta-analysis of 36 trials 60 
(12,526 participants from 16 countries; 50 investigators) on the effect of diet and physical 61 
activity based interventions in pregnancy6 as an exemplar (Appendix 1). 62 
 63 
Standardisation of data across trials 64 
Access to IPD should create a unique opportunity to unify all essential data. This is true 65 
assuming that collected data can be brought to the same format without losing their value. 66 
Routinely collected data such as age, weight or height tend to be captured as real values 67 
making them relatively easy to harmonise. Participant characteristics recorded in other 68 
formats or those less routinely collected can be much more challenging to standardize. One of 69 
the subgroups of interest in the project was maternal ethnic origin7. The characteristic was 70 
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available for 47% (17/36) trials of which one differentiated only between indigenous and 71 
non-indigenous women, four classified women only as Caucasian or non-Caucasian, and 72 
eight declared to include only Caucasians or not recognise “ethnicity” in their country. The 73 
characteristic was grouped into six categories (Caucasian, Asian, Afro-Caribbean, Central 74 
and South American, Middle Eastern, other and unknown) but due to a low proportion of 75 
women from groups other than Caucasian (>80% of included women) in the analysis of 76 
differential effects of intervention by ethnic origin the characteristic was used in the binary 77 
format (Caucasian/non-Caucasian).6 78 
 79 
Harmonisation of outcome definitions faced similar challenges. While some definitions are 80 
relatively easy to bring to a common format across the trials e.g. preterm birth, 81 
standardisation of others was simply not feasible. The task can be even more daunting when 82 
there is no consensus on classification methods, or the definitions changed over the years. 83 
Despite access to IPD, direct communication with the research teams and the idea 84 
endorsement by the members of the i-WIP collaborative group, standardisation of outcomes 85 
such as gestational diabetes (GDM) or caesarean section turned out to be unachievable within 86 
the study funding time. Diagnosis of GDM was based on a broad range of guidelines that 87 
followed algorithms that did not always overlap with each other. We have  made an attempt 88 
to standardise the definitions of GDM and collected the blood test measurements used to 89 
diagnosis the condition. However, the variability in glucose loads (50, 75 or 100 grammes) 90 
and tests’ timing (fasting, 1 hour or 2 hours) lead us to abandon this task and acknowledge 91 
the variability in the outcome definition as a limitation. The variety of GDM definitions and 92 
the blood test measures, as well as the coding of participants ethnic origin in the trials with 93 
diet and/or physical activity in pregnancy, is presented in Appendix 2. 94 
 95 
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Unreported outcomes 96 
Selective reporting of intervention effects depending on statistical significance is one of the 97 
most important sources of bias affecting clinical trials.8-11 Despite clear guidance on reporting 98 
of outcomes in the trial reports12, the problem persists, having a serious impact on the meta-99 
analysis. In combination with variation in choice of trial outcomes13, they are contributing to 100 
the serious waste of research efforts. More frequent reporting of statistically significant 101 
results can lead to a potential overestimation of underlying treatment effects in a meta-102 
analysis when using data extracted from trial publications. IPD meta-analysis has the 103 
potential to address this problem through facilitating analysis of core outcome sets14, if 104 
available in trial datasets but not reported in publications. 105 
 106 
Access to individual records should increase the number of trials included in the analysis and 107 
enhance the quality of outcome data. However, the benefits may not always be substantial. In 108 
the i-WIP project, the number of trials with the outcomes of interest was higher through 109 
access to IPD in comparison to data extracted from publications (Appendix 3). Additionally, 110 
use of the raw data to generate outcomes not considered in original trials (e.g. use of 111 
gestational age at delivery to define the occurrence of prematurity) may lead to a substantial 112 
increase in the number of the trial that can be incorporated into the meta-analysis (Table 2). 113 
Even so, the presence of data in the dataset did not always allow to incorporate a given 114 
dataset in the statistical analysis. Too few events (e.g. stillbirths) and lack of all measures 115 
(baseline and final for weight gain) prevented trial inclusion. Still, in the example 116 
incorporation of trials with previously unavailable outcome data changed the value of the 117 
effect estimate by more than 10% in three outcomes and its statistical significance in one 118 
(Table 2). 119 
 120 
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The addition of unreported data may or may not lead to a change in funnel plot asymmetry. In 121 
the example, incorporation of unpublished outcomes in the meta-analysis for admission to 122 
neonatal intensive care unit has not revealed any potential bias. Similarly, for small for 123 
gestational age infant where outcome data were generated uing raw data if the outcome was 124 
not considered in original trials (Table 2). For continuous outcomes (gestational weight gain 125 
in the example) the change in the plot asymmetry might also occur due to the standardisation 126 
of the analysis methods rather than incorporation of unreported data (Figure 1). 127 
 128 
Role of IPD meta-analysis in dynamic research areas 129 
The authors of guidance on the appraisal of IPD meta-analyses of randomised trials advocate 130 
checking for the proportion of trials from which IPD was obtained.5 A recent study showed 131 
that only 25% of evaluated IPD meta-analyses obtained 100% of identified trial 132 
data.15Acquisition of all eligible trials can be challenging for numerous reasons, with 133 
uncooperative trial investigators mentioned most commonly.5 IPD meta-analysis is a lengthy 134 
and resource intensive process which can also decrease the chance of complying with the 135 
above mentioned recommendation. 136 
 137 
Since the publication of the systematic review that laid the grounds for the IPD meta-analysis 138 
we used as an example16, there has been a significant increase in the number of trials 139 
evaluating the effects of diet and/or physical activity based interventions in pregnancy. 140 
Between the end of data acquisition in June 2015 to February 2017 findings from additional 141 
45 trials have been published (Figure 2) making achieving the goal of being up to date and 142 
obtaining the majority of IPD virtually impossible.17 In combination with the trials for which 143 
IPD was sought but not obtained, the number of trials outside the IPD meta-analysis (non-144 
IPD studies) constituted 65% of trials (67/103 trials) and 51% of women randomised to all 145 
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eligible trials (12,960/25,486). The meta-analysis combining IPD with non-IPD studies, 146 
showed a stronger overall effect of interventions in reduction of gestational weight gain and a 147 
significant reduction of odds for GDM then one using only IPD.17 148 
 149 
Summary 150 
Despite the advantages of meta-analysis using IPD, the method encounters problems faced by 151 
other research methods such as uncooperative investigators or incompleteness of records. The 152 
IPD meta-analysis is a resource-demanding approach to evidence synthesis and requires a 153 
thorough evaluation of what is achievable. It might be that we will need to accept that some 154 
primary research is not usable for evidence synthesis. Mapping of definitions and additional 155 
data that could help to standardise the outcome across the trials may not tackle all the issues, 156 
but will facilitate the smoother conduct of IPD meta-analyses. The efforts associated with 157 
obtaining IPD and its harmonisation need to be balanced by the potential gains achievable 158 
through a complex and profound statistical analysis. Prospectively designed IPD meta-159 
analyses have the potential to overcome some of the challenges described in this article as 160 
they tend to collect data in a preagreed format18. Promotion of consensus on the research 161 
standards with regards to outcome definitions, capturing of participants’ characteristics, and 162 
effective ways implementing them in the trials should help to reduce the potential research 163 
waste. Finally, putting the findings of IPD meta-analysis into a context of the totality of 164 
evidence is paramount for the validity of results. (ref) Currently guidelines recommend 165 
adding non-IPD studies to IPD meta-analysis when a substantial proportion of trials IPD was 166 
not obtained at the beginning of the project. Additionally, in some areas of medical research 167 
the amount of evidence generated annually makes it difficult to stay up to date while 168 
conducting IPD meta-analysis. Therefore, adding newly published trials is as important as 169 
incorporating the not shared ones.    170 
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